The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Koalas from a population north of the Brisbane River have evolved a unique genomic immunity to the killer retrovirus ...

Dr K K Pandey Either during your childhood or at young age,you would have noticed a protruding swelling or solid tumour like ...

The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...

总的来说，该研究为 ACEi 和 ARBs 在预防 CTRC 方面的应用提供了重要参考，尽管未能明确其预防 CTRC 的效果，但在改善左心室功能方面的发现为后续研究指明了方向，有望推动癌症治疗中心脏保护策略的进一步发展。

The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study,” published in the March 2025 issue of Journal of the ...

You hear Brian O’Sullivan’s booming, friendly voice in the building before you see him. He seems to know everyone, greeting ...